BioSpace News Archive

December 12, 2023 – The AIDS and Cancer Specimen Resource (ACSR), a biorepository of specimens collected from persons living with HIV (PLWH) established in 1994 and funded by the National Institutes of Health

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) announces that at the 2023 American Society of Hematology (“ASH”) Annual Meeting, the Company presented one poster with study results for zevorcabtagene autoleucel (“zevor-cel”, R&D code: CT053, an autologous CAR T-cell therapy candidate against BCMA), which include the 3-year follow-up on efficacy and safety results from the Phase I portion of Phase I/II registrational study in China (LUMMICAR-1, NCT03975907).

Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) (“Justera” or the “Company”) is pleased to announce changes to its management.

BillionToOne (BTO) is pleased to announce a global collaboration with Janssen Research & Development, LLC, a Johnson & Johnson company (Johnson & Johnson), in the AZALEA Phase 3 clinical trial of nipocalimab in pregnancies at risk for severe hemolytic disease of the fetus and newborn (HDFN).

Psycheceutical Bioscience, Inc. is thrilled to announce the appointment of Dr. Neilank K. Jha as its new Executive Chairman and Chief Executive Officer.

BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® program.

Cassava Sciences, Inc. announced a pro rata dividend distribution of warrants to holders of the Company’s common stock as of December 22, 2023.

Zeteo Tech, Inc. announced that it has been awarded a Phase III Small Business Innovation Research contract for $1.87M with a potential value of up to $5.86 million from the U.S. Department of Homeland Security.

BostonGene, a leading AI-based molecular and immune profiling solutions provider, and the Sarcoma Oncology Center, announced a collaboration to expedite the availability of DeltaRex-G.

Humanetics Corporation, a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies, has announced the addition of Major General Barbara R. Holcomb, RN, BSN, MSN to its board of directors.